PT3065761T - Método de tratamento de condições oculares com um darpin anti-vegf - Google Patents
Método de tratamento de condições oculares com um darpin anti-vegfInfo
- Publication number
- PT3065761T PT3065761T PT148025448T PT14802544T PT3065761T PT 3065761 T PT3065761 T PT 3065761T PT 148025448 T PT148025448 T PT 148025448T PT 14802544 T PT14802544 T PT 14802544T PT 3065761 T PT3065761 T PT 3065761T
- Authority
- PT
- Portugal
- Prior art keywords
- eye
- treating conditions
- vegf darpin
- darpin
- vegf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361900246P | 2013-11-05 | 2013-11-05 | |
US201462016620P | 2014-06-24 | 2014-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3065761T true PT3065761T (pt) | 2020-02-21 |
Family
ID=51947485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT148025448T PT3065761T (pt) | 2013-11-05 | 2014-11-04 | Método de tratamento de condições oculares com um darpin anti-vegf |
Country Status (14)
Country | Link |
---|---|
US (4) | US20150126458A1 (pt) |
EP (2) | EP3065761B1 (pt) |
JP (3) | JP2016536369A (pt) |
KR (1) | KR20160070164A (pt) |
CN (1) | CN105960247A (pt) |
AU (2) | AU2014346921A1 (pt) |
CA (1) | CA2927012A1 (pt) |
DK (1) | DK3065761T3 (pt) |
ES (1) | ES2773317T3 (pt) |
HU (1) | HUE047910T2 (pt) |
PL (1) | PL3065761T3 (pt) |
PT (1) | PT3065761T (pt) |
TW (1) | TWI729970B (pt) |
WO (1) | WO2015069668A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0710645A2 (pt) | 2006-04-07 | 2012-03-20 | The Procter & Gamble Company | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos |
WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
WO2013169614A1 (en) | 2012-05-07 | 2013-11-14 | Allergan, Inc. | Method of treating amd in patients refractory to anti-vegf therapy |
EP3790532A1 (en) | 2018-05-10 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
CN113164597A (zh) | 2018-09-24 | 2021-07-23 | 爱尔皮奥制药公司 | 靶向HPTP-β(VE-PTP)和VEGF的多特异性抗体 |
WO2020245173A1 (en) * | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
CN116710135A (zh) * | 2020-10-07 | 2023-09-05 | 6线生物技术公司 | 用于治疗眼部疾病的方法和试剂 |
CN114075290B (zh) * | 2022-01-20 | 2022-04-19 | 南京鼓楼医院 | Cd40靶向结合蛋白、其编码核酸以及用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0011407B8 (pt) | 1999-06-08 | 2021-05-25 | Regeneron Pharma | molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão |
EP2149604A1 (en) | 2000-09-08 | 2010-02-03 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
PL2173890T3 (pl) | 2007-06-21 | 2011-07-29 | Univ Muenchen Tech | Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro |
NZ592591A (en) * | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
AR081361A1 (es) * | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
WO2013169614A1 (en) * | 2012-05-07 | 2013-11-14 | Allergan, Inc. | Method of treating amd in patients refractory to anti-vegf therapy |
-
2014
- 2014-11-04 PL PL14802544T patent/PL3065761T3/pl unknown
- 2014-11-04 CN CN201480060463.5A patent/CN105960247A/zh active Pending
- 2014-11-04 HU HUE14802544A patent/HUE047910T2/hu unknown
- 2014-11-04 EP EP14802544.8A patent/EP3065761B1/en active Active
- 2014-11-04 ES ES14802544T patent/ES2773317T3/es active Active
- 2014-11-04 PT PT148025448T patent/PT3065761T/pt unknown
- 2014-11-04 DK DK14802544.8T patent/DK3065761T3/da active
- 2014-11-04 AU AU2014346921A patent/AU2014346921A1/en not_active Abandoned
- 2014-11-04 EP EP19192065.1A patent/EP3628324A1/en not_active Withdrawn
- 2014-11-04 WO PCT/US2014/063951 patent/WO2015069668A1/en active Application Filing
- 2014-11-04 US US14/532,397 patent/US20150126458A1/en not_active Abandoned
- 2014-11-04 JP JP2016552455A patent/JP2016536369A/ja active Pending
- 2014-11-04 KR KR1020167014741A patent/KR20160070164A/ko not_active Application Discontinuation
- 2014-11-04 CA CA2927012A patent/CA2927012A1/en not_active Abandoned
- 2014-11-05 TW TW103138456A patent/TWI729970B/zh active
-
2016
- 2016-08-05 US US15/230,244 patent/US20170157207A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,290 patent/US20210008158A1/en not_active Abandoned
- 2020-05-05 AU AU2020202968A patent/AU2020202968A1/en not_active Abandoned
- 2020-06-22 JP JP2020106978A patent/JP2020169191A/ja active Pending
-
2021
- 2021-10-13 US US17/500,315 patent/US20220175881A1/en not_active Abandoned
-
2022
- 2022-05-06 JP JP2022076645A patent/JP2022107628A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220175881A1 (en) | 2022-06-09 |
CN105960247A (zh) | 2016-09-21 |
US20210008158A1 (en) | 2021-01-14 |
AU2014346921A1 (en) | 2016-06-02 |
US20150126458A1 (en) | 2015-05-07 |
WO2015069668A1 (en) | 2015-05-14 |
TW201609125A (zh) | 2016-03-16 |
TWI729970B (zh) | 2021-06-11 |
JP2016536369A (ja) | 2016-11-24 |
JP2022107628A (ja) | 2022-07-22 |
EP3628324A1 (en) | 2020-04-01 |
DK3065761T3 (da) | 2020-02-17 |
HUE047910T2 (hu) | 2020-05-28 |
KR20160070164A (ko) | 2016-06-17 |
EP3065761B1 (en) | 2020-01-08 |
EP3065761A1 (en) | 2016-09-14 |
US20170157207A1 (en) | 2017-06-08 |
PL3065761T3 (pl) | 2020-05-18 |
JP2020169191A (ja) | 2020-10-15 |
ES2773317T3 (es) | 2020-07-10 |
AU2020202968A1 (en) | 2020-05-21 |
CA2927012A1 (en) | 2015-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286808A (en) | System and methods for ocular injection | |
IL278018A (en) | Methods for the treatment or prevention of ophthalmological conditions | |
HK1222791A1 (zh) | 用於眼睛的光線療法的裝置 | |
HK1225654A1 (zh) | 用於治療老花眼的組合物及方法 | |
HK1217908A1 (zh) | 治療膽管癌的方法 | |
DK3057993T3 (en) | Method for Treating Conditions Associated with MASP-2 Dependent Complement | |
HK1248552A1 (zh) | 使用川地匹坦的治療方法 | |
HUE047910T2 (hu) | Eljárás a szem állapotainak kezelésére anti-VEGF darpinnal | |
HK1232235A1 (zh) | 治療和診斷過表達α- -β- 的癌症的方法 | |
EP2971944A4 (en) | MULTI-LENS MONOBLOC OPTICAL ELEMENT AND METHOD OF MANUFACTURE | |
SI3027564T1 (sl) | Talilnik in postopek za zakrito zgorevanje | |
IL251769A0 (en) | Methods for treating eye conditions | |
EP3079679A4 (en) | Method of treatment of alopecia with monoterpenoids | |
HK1249866A1 (zh) | 用他塞利昔布進行治療的方法 | |
GB201501315D0 (en) | Submerged combustion melters and methods | |
GB201421861D0 (en) | Method of aquiring fuel injector characteristics | |
SG10201802808SA (en) | Method of treating ocular disorders | |
GB201317835D0 (en) | Bottle and method for the introduction of an additive into a central heating radiator | |
EP2959018A4 (en) | METHODS OF EVALUATION OF THE DEVELOPMENT RISK OF CANINE ATOPIC DERMATITIS |